Johnson & Johnson Announced At ESMO Saturday, Phase 3 PROTEUS Substudy Data Showing Perioperative Apalutamide Plus ADT Reduced Risk Of Disease Recurrence Or Death By 62%, Metastasis Or Death By 51% Vs. Surgery Alone In High-Risk Prostate Cancer

Loading news article.

Johnson & Johnson Announced At ESMO Saturday, Phase 3 PROTEUS Substudy Data Showing Perioperative Apalutamide Plus ADT Reduced Risk Of Disease Recurrence Or Death By 62%, Metastasis Or Death By 51% Vs. Surgery Alone In High-Risk Prostate Cancer | WAPE

Johnson & Johnson Announced At ESMO Saturday, Phase 3 PROTEUS Substudy Data Showing Perioperative Apalutamide Plus ADT Reduced Risk Of Disease Recurrence Or Death By 62%, Metastasis Or Death By 51% Vs. Surgery Alone In High-Risk Prostate Cancer

Article summary

Related companies

Comments —